1. Home /
    2. Altai Protocol Library /
  2. New Reference: Ripretinib Versus Sunitinib in Patients With Advanced Gastrointestinal Stromal Tumor

Altai Protocol Library

1041 protocols and counting

All protocols with references and links

All protocols reviewed by a Medical Oncologist/Hematologist

All protocols in major guidelines included

Ability to create your own protocols

Search Library Posts Search
Altai Protocol Library

New Reference: Ripretinib Versus Sunitinib in Patients With Advanced Gastrointestinal Stromal Tumor

New Reference: Ripretinib Versus Sunitinib in Patients With Advanced Gastrointestinal Stromal Tumor
Study:
  • Randomized, open-label, international, multicenter phase III study
  • Advanced GIST who progressed on or were intolerant to first-line treatment with imatinib
  • Ripretinib 150 mg (n = 226) or sunitinib 50 mg (4/2, n = 227)
Efficacy:
  • mPFS: 8.3 m vs 7 months (HR, 0.88; P = .36) for KIT exon 11 ITT
  • ORR: 23.9% v 14.6%, P = .03
Safety:
  • Grade ≥3 AEs: 26.5% vs 55.2%
  • Drug related death: 0 vs 0.5%
  • Any grade TRAE: alopecia (64.1%), fatigue (37.7%), myalgia (36.3%) for ripretinib and Palmar-plantar erythrodysesthesia syndrome (51.1%), diarrhea (48.0%), hypertension (47.1%) for sunitinib

J Clin Oncol. 2022 Aug 10;JCO2200294.

Bauer S, Jones RL, Blay JY, et al. Ripretinib Versus Sunitinib in Patients With Advanced Gastrointestinal Stromal Tumor After Treatment With Imatinib (INTRIGUE): A Randomized, Open-Label, Phase III Trial

https://doi.org/10.1200/jco.22.00294

Reviewed by Hasan Çağrı Yıldırım, MD on Aug 16, 2022

Altai Chemo Planner

Quickly Prepare Accurate Chemotherapy Orders

Altai Chemo Planner employs Altai Protocol Library that includes over 1000 chemotherapy protocols for both Hematology and Oncology. You can find major guidelines' protocols, parenteral, and oral, in the library. Altai Protocol Library is frequently and regularly updated.

Learn More